Exelixis to Present at the RBC Capital Markets Global Healthcare Conference on February 21, 2018

Presentation to be webcast on www.exelixis.com

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s President and Chief Executive Officer, will provide
an overview of the company at the RBC Capital Markets Global Healthcare
Conference taking place February 21-22 in New York, NY. The Exelixis
presentation is scheduled for 11:30 a.m. EST / 8:30 a.m. PST on
Wednesday, February 21, 2018.

To access the webcast link, log onto www.exelixis.com
and proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s website at
least 15 minutes prior to the presentation to ensure adequate time for
any software download that may be required to listen to the webcast. A
replay will also be available at the same location for 14 days.

About Exelixis

Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. We discovered our lead
compounds, cabozantinib and cobimetinib, and advanced them into clinical
development before entering into partnerships with leading
biopharmaceutical companies in our efforts to bring these medicines to
patients globally. We are steadfast in our commitment to prudently
reinvest in our business to maximize the potential of our pipeline. We
intend to supplement our existing therapeutic assets with targeted
business development activities and internal drug discovery — all to
deliver the next generation of Exelixis medicines and help patients
recover stronger and live longer. Exelixis recently earned a spot on
Deloitte’s Technology Fast 500 list, a yearly award program honoring the
500 fastest-growing companies over the past four years. For more
information about Exelixis, please visit www.exelixis.com
or follow @ExelixisInc on Twitter.

Exelixis and the Exelixis logo are registered U.S. trademarks.

Contacts

Investors Contact:
Exelixis, Inc.
Susan
Hubbard, 650-837-8194

EVP, Public Affairs and Investor
Relations

shubbard@exelixis.com
or
Media
Contact:

For Exelixis, Inc.
Hal Mackins,
415-994-0040

hal@torchcommunications.com